Research ArticleClinical Studies
The Evaluation of E-Cadherin and Vimentin as Biomarkers of Clinical Outcomes Among Patients with Non-small Cell Lung Cancer Treated with Erlotinib as Second- or Third-line Therapy
FRANK RICHARDSON, G DAVID YOUNG, REGINA SENNELLO, JULIE WOLF, GRETCHEN M. ARGAST, PETER MERCADO, ANGELA DAVIES, DAVID M. EPSTEIN and BRET WACKER
Anticancer Research February 2012, 32 (2) 537-552;